TG Therapeutics, Inc.
NASDAQ:TGTXBiotechnology
+$1.03 today
- Market cap
- $9.99B
- Beta
- 1.68
- P/E (TTM)
- 16.4
- EPS (TTM)
- $3.20
Volume 1.87M
Average 2.15M
TGTX Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
TG Therapeutics, Inc.NASDAQ: TGTX
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue grows, but more slowly than its trailing trend
Q3 FY2026 cost of revenue of $42.08M rose 49.5% year over year, behind the +98.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 2.1% from the prior quarter. Over 3 fiscal years it compounded at +624.3% a year.
Context
- Cost of revenue amounted to 16.3% of revenue in FY2025, up 4.6 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +49.5% toward the trailing-twelve-month pace of +98.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 100.71M USD
- Year-over-year change
- +161.7%
- 4-year CAGR
- +236.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 100.71M | +161.7% |
| FY2024 | 2024-12-31 | 38.49M | +172.4% |
| FY2023 | 2023-12-31 | 14.13M | +5232.5% |
| FY2022 | 2022-12-31 | 265K | -66.5% |
| FY2021 | 2021-12-31 | 790K | — |
Cost of Revenue vs competitors
How TGTX compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +98.5% is the highest of 6, against a peer median of -18.4%.
- Cost of revenue amounts to 17.3% of revenue for TGTX, versus a peer median of 30.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $288M USD | — | — | 7.0% | |
| LTM Sep 2026 | $154.93M USD | +98.5% | +624.3% | 17.3% | |
| LTM Jun 2026 | $59.51M USD | -6.4% | -62.5% | 56.7% | |
| LTM Mar 2026 | $47.23M USD | -18.4% | +80.2% | 30.1% | |
| LTM Mar 2026 | $7.35M USD | +33.7% | +32.5% | 9.3% | |
| LTM Sep 2026 | $854K USD | -99.5% | — | 762.5% | |
| LTM Jun 2024 | $425.46K USD | — | — | 52.2% | |
| LTM Mar 2026 | $55K USD | — | — | — | |
| FY2025 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding TGTX) | — | -18.4% | +32.5% | 30.1% | |
Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.69M | 2.79M | 233.66M | 329M | 616.29M |
| Cost of Revenue | 790K | 265K | 14.13M | 38.49M | 100.71M |
| Gross Profit | 5.9M | 2.52M | 219.53M | 290.52M | 515.57M |
| Gross Margin | 88.2% | 90.5% | 94.0% | 88.3% | 83.7% |
| Research & Development | 222.58M | 125.35M | 76.19M | 94.29M | 160.22M |
| Selling, General & Admin | 128.09M | 95.48M | 122.71M | 154.3M | 232.03M |
| Operating Expenses | 350.67M | 220.84M | 198.9M | 248.59M | 392.25M |
| Depreciation & Amortization | 494K | 515K | 423K | 280K | 244K |
| EBITDA | (341.97M) | (213.11M) | 26.1M | 49.9M | 134.36M |
| EBITDA Margin | -5112.4% | -7651.9% | 11.2% | 15.2% | 21.8% |
| Operating Income | (344.77M) | (218.32M) | 20.63M | 41.93M | 123.32M |
| Operating Margin | -5154.3% | -7839.0% | 8.8% | 12.7% | 20.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 5.64M | 10.19M | 12.62M | 24.03M | 26.73M |
| Other Income / Expenses | (3.33M) | (5.5M) | (7.57M) | (16.34M) | (15.93M) |
| Income Before Tax | (348.1M) | (223.81M) | 13.06M | 25.59M | 107.39M |
| Pre-Tax Margin | -5204.1% | -8036.3% | 5.6% | 7.8% | 17.4% |
| Income Tax Expense | 0 | 0 | 390K | 2.21M | (339.79M) |
| Net Income | (348.1M) | (223.81M) | 12.67M | 23.38M | 447.18M |
| Net Margin | -5204.1% | -8036.3% | 5.4% | 7.1% | 72.6% |
| EPS (Basic) | (2.63) | (1.46) | 0.09 | 0.16 | 3.10 |
| EPS (Diluted) | (2.63) | (1.46) | 0.09 | 0.15 | 2.77 |
| Weighted Avg Shares | 132.22M | 135.41M | 141.96M | 145.32M | 144.32M |
| Weighted Avg Shares (Diluted) | 132.22M | 135.41M | 148.51M | 160.34M | 161.41M |
TG Therapeutics, Inc.
NASDAQ:TGTX
Intrinsic Alpha fair value
Locked
Current Price
$66.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.